ProShare Advisors
BLCM

ProShare Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

ProShare Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,260
Closed -$139K – 1737
2018
Q3 		$139K Sell
2,260
-66
-3% -$4.47K ﹤0.01% 1647
2018
Q2 		$172K Buy
2,326
+441
+23% +$34.4K ﹤0.01% 1641
2018
Q1 		$124K Sell
1,885
-310
-14% -$23.4K ﹤0.01% 1621
2017
Q4 		$185K Buy
2,195
+137
+7% +$13.4K ﹤0.01% 1658
2017
Q3 		$238K Buy
2,058
+119
+6% +$12.5K ﹤0.01% 1224
2017
Q2 		$227K Buy
1,939
+251
+15% +$31.2K ﹤0.01% 1287
2017
Q1 		$208K Sell
1,688
-440
-21% -$57.6K ﹤0.01% 1437
2016
Q4 		$290K Buy
2,128
+216
+11% +$38.3K ﹤0.01% 1387
2016
Q3 		$381K Sell
1,912
-353
-16% -$60.8K 0.01% 1058
2016
Q2 		$294K Buy
2,265
+216
+11% +$24K ﹤0.01% 1223
2016
Q1 		$192K Sell
2,049
-203
-9% -$22.1K ﹤0.01% 1433
2015
Q4 		$456K Buy
+2,252
New +$403K 0.01% 1074

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's BLCM Position: Q4 2018 in Review

ProShare Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2018, closing a stake of 2,260 shares — an estimated $139K sold.

ProShare Advisors first reported a position in BLCM in Q4 2015 and held it in 12 quarters. The position peaked at $456K in Q4 2015. 92 funds tracked by Wall St. Rank hold BLCM as of Q4 2018.

  • ProShare Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • ProShare Advisors sold 2,260 Bellicum Pharmaceuticals, Inc. shares in Q4 2018, an estimated $139K.
  • ProShare Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2015 and held it in 12 quarters.
  • ProShare Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $456K in Q4 2015.
  • 92 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2018.

Based on ProShare Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.